Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $12.5 to $13.
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $12.5 to $13.